19 December 2024 : Clinical Research
Impact of Dual Antithrombotic Therapy with Aspirin and Rivaroxaban on Secondary Cardiovascular Outcomes
Wei Li ACDE 1*, Yi Li BEF 2, Chen Liu DE 1, Jinghao Yuan BCDE 1, Weize Fan CDEF 1, Qing Miao BEF 1, Xinshun Gu ADE 1DOI: 10.12659/MSM.945457
Med Sci Monit 2024; 30:e945457
Table 2 Primary outcome of both groups.
| Outcomes | Aspirin group (n=84) | Aspirin + rivaroxaban group (n=84) | P value |
|---|---|---|---|
| Recurrent myocardial infarction | 2 (2.38%) | 1 (1.19%) | 1.000 |
| Stent restenosis | 2 (2.38%) | 0 (0.0%) | 0.497 |
| Coronary target vessel revascularization | 1 (1.19%) | 0 (0.0%) | 1.000 |
| Intrastent thrombosis | 1 (1.19%) | 0 (0.0%) | 1.000 |
| Heart failure | 2 (2.38%) | 1 (1.19%) | 1.000 |
| Readmission | 5 (5.95%) | 3 (3.57%) | 0.720 |
| All-cause death | 3 (3.57%) | 1 (1.19%) | 0.620 |
| Total MACE | 11 (13.10) | 3 (3.57%) | 0.026 |
| MACE – major adverse cardiovascular events. | |||